Trinity Capital Injects $50M into Cala Health for Wearable Tremor Therapy Expansion
Event summary
- Trinity Capital Inc. committed $50 million in growth capital to Cala Health on April 20, 2026.
- Cala Health's Cala kIQ® System is an FDA-cleared wearable device for managing hand tremors in essential tremor and Parkinson's disease patients.
- The funding will support Cala Health's commercial expansion and product innovation.
- Trinity Capital has deployed over $5.5 billion across 463 investments since its inception in 2008.
The big picture
Trinity Capital's investment in Cala Health underscores the growing interest in bioelectronic medicine and wearable health technologies. The deal highlights the strategic importance of non-invasive, personalized therapies in managing chronic conditions like essential tremor and Parkinson's disease. With over $5.5 billion in deployments, Trinity Capital's backing signals confidence in Cala Health's ability to scale and innovate in a competitive healthcare landscape.
What we're watching
- Market Penetration
- How Cala Health will leverage the $50 million to accelerate its commercial expansion and increase market share in wearable tremor therapy.
- Product Innovation
- Whether the funding will drive significant advancements in Cala Health's product line, particularly in personalized neuromodulation therapies.
- Regulatory Compliance
- The pace at which Cala Health can navigate regulatory hurdles to expand the use of its FDA-cleared device into new markets or indications.
Related topics